TORRENT PHARMACEUTICALS LTD. - 500420 - Shareholding for the Period Ended December 31, 2021
Torrent Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2021. For more details, kindly Click here TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
We hereby inform that the Company has scheduled a teleconference with Investors / Analyst on 25th January, 2022 at 06:00 P.M. to discuss the financial performance of the Company for the quarter and nine months ended 31st December, 2021. TORRENT PHARMACEUTICALS LTD. - 500420 - Fiexes Record Date for lnterim Dividend
Torrent Pharmaceuticals Ltd has informed BSE that the Company has fixed February 03, 2022 as the Record Date for the purpose of payment of lnterim Dividend, if declared. TORRENT PHARMACEUTICALS LTD. - 500420 - Corporate Action-Board to consider Dividend
Pursuant to Regulation 42 of Listing Regulations, the Company has fixed Thursday, 3rd February, 2022 as the Record Date for taking record of the Members of the Company for the purpose of payment of Interim Dividend, if declared by the Board at their meeting scheduled to be held on Tuesday, 25th January, 2022. TORRENT PHARMACEUTICALS LTD. - 500420 - Board Meeting Intimation for Intimation Of The Date Of Board Meeting Under Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
TORRENT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/01/2022 ,inter alia, to consider and approve We would like to inform you that the meeting of the Board of Directors will be held on Tuesday, 25-Jan-22, inter alia, to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter and nine months ended on 31-Dec-21. The Board would also consider payment of Interim Dividend for the year 2021-22. TORRENT PHARMACEUTICALS LTD. - 500420 - Statement Of Investor Complaints For The Quarter Ended December 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0220 Name of the Signatory :- Mahesh AgrawalDesignation :- Company Secretary and Compliance Officer TORRENT PHARMACEUTICALS LTD. - 500420 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Issue of Duplicate Share Certificate TORRENT PHARMACEUTICALS LTD. - 500420 - Closure of Trading Window
Pursuant to Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons of the Company (''Code'') and applicable SEBI Regulations, we would like to inform you that trading window for dealing in securities of the Company by Designated Persons stands closed from 1st January, 2022 and will be re-opened 48 hours after the submission of the Financial Results for the Quarter and nine months ended 31st December, 2021 to the Stock Exchanges.
Torrent Pharma to launch Molnupiravir under brand name Molnutor in India
The Drugs Controller General of India (DCGI), based on the review of clinical data of Molnupiravir has approved the drug for the treatment of Covid-19 in adults for restricted emergency use in India